Table 1.
Characteristics of the study population at baseline and at the last screening
| All (n=6964) | Men (n=4866) | Women (n=2098) | ||
|---|---|---|---|---|
| Baseline examination | ||||
| Age, years | 50·0 (6·0) | 49·8 (6·0) | 50·5 (6·1) | |
| Systolic blood pressure, mm Hg | 120·4 (13·5) | 121·7 (13·1) | 117·4 (13·9) | |
| Total cholesterol, mmol/L | 6·5 (1·1) | 6·5 (1·1) | 6·5 (1·2) | |
| HDL cholesterol, mmol/L | 1·4 (0·4) | 1·3 (0·4) | 1·7 (0·4) | |
| Diabetes | 137 (2%) | 97 (2%) | 40 (2%) | |
| Current smoker | 939 (13%) | 601 (12%) | 338 (16%) | |
| Antihypertensive treatment | 450 (6%) | 265 (5%) | 185 (9%) | |
| 10-year risk category at baseline | ||||
| Original ASCVD | ||||
| <2·5% (low) | 2612 (38%) | 1174 (24%) | 1438 (69%) | |
| 2·5% to <5% (intermediate-low) | 1857 (27%) | 1403 (29%) | 454 (22%) | |
| 5% to <7·5% (intermediate-high) | 1024 (15%) | 894 (18%) | 130 (6%) | |
| ≥7·5% (high) | 1471 (21%) | 1395 (29%) | 76 (4%) | |
| Revised ASCVD | ||||
| <2·5% (low) | 3733 (54%) | 2207 (45%) | 1526 (73%) | |
| 2·5% to <5% (intermediate-low) | 2119 (30%) | 1713 (35%) | 406 (19%) | |
| 5% to <7·5% (intermediate-high) | 653 (9%) | 547 (11%) | 106 (5%) | |
| ≥7·5% (high) | 459 (7%) | 399 (8%) | 60 (3%) | |
| 10-year risk category at fourth follow-up | ||||
| Number of patients | 4985 | 3581 | 1404 | |
| Original ASCVD | ||||
| <2·5% (low) | 51 (1%) | 0 | 51 (4%) | |
| 2·5% to <5% (intermediate-low) | 288 (6%) | 18 (1%) | 270 (19%) | |
| 5% to <7·5% (intermediate-high) | 406 (8%) | 163 (5%) | 243 (17%) | |
| ≥7·5% (high) | 4240 (85%) | 3400 (95%) | 840 (60%) | |
| Revised ASCVD | ||||
| <2·5% (low) | 314 (6%) | 92 (3%) | 222 (16%) | |
| 2·5% to <5% (intermediate-low) | 1377 (28%) | 943 (26%) | 434 (31%) | |
| 5% to <7·5% (intermediate-high) | 1149 (23%) | 846 (24%) | 303 (22%) | |
| ≥7·5% (high) | 2145 (43%) | 1700 (47%) | 445 (32%) | |
Data are mean (SD) or number (%). ASCVD=Atherosclerotic Cardiovascular Disease.